PU Conference Series: Euretina 2018

† Supported by over 10 years of clinical evidence. 1 PROVEN †

With over a decade of safety and efficacy data, patients can take confidence in the only anti-VEGF available in a pre-filled syringe. 1–3

NEW

nAMD

DME

BRVO CRVO

mCNV other CNV

BRVO, branch retinal vein occlusion; CNV, choroidal neovascularisation; CRVO, central retinal vein occlusion; DME, diabetic macular oedema; mCNV, myopic choroidal neovascularisation; nAMD, neovascular age-related macular degeneration; VEGF, vascular endothelial growth factor.

References: 1 . Lucentis ® Product Information. August 2017. 2. Souied E et al. Eur J Ophthalmol 2015; 25 (6): 529–534. 3. Pharmaceutical Benefits Scheme. Ranibizumab syringe. www.pbs.gov.au/medicine/item/10138N-10374B (accessed 16 May 2018). Novartis Pharmaceuticals Australia Pty Limited. ABN 18 004 244 160. 54 Waterloo Road, Macquarie Park, NSW 2113. ® Registered Trademark. AU-7317. McCann Health NOLU14800M/PUCS. September 2018. Before prescribing, please review PBS and product information available in the primary advertisement of this publication. PBS Information: Authority required for the treatment of wet AMD, DME, BRVO and CRVO. Refer to PBS Schedule for full Authority information. This product is not PBS listed for the treatment of CNV secondary to PM or to causes other than wet AMD.

POWERFUL. PRECISE. PROVEN.